Frenetic Pace of Activity in IVD Over Past Two Years: Kalorama Reports
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 08/21/12 -- A large number of acquisitions and partnerships occurred in the industry over the past two years, a sign of the frenetic pace of the industry, according to Kalorama Information. The said there were at least 105 acquisitions and distribution agreements in the market just in the past two years, the majority of which were acquisitions. Kalorama Information's recent report, "," suggests the activity will continue.
"The future of the industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a host of new protein and molecular markers," said Shara Rosen, R.T. MBA, the author and lead diagnostic analyst for Kalorama Information. "No company, big or small, owns all of the technology needed to develop these new tests and systems."
The report cites some examples of acquisitions that have occurred since 2010:
Danaher Corporation purchased IVD leader Beckman Coulter
Agilent Technologies purchased FISH/IHC leader Dako
Roche entered a development agreement with Dexcom for its SEVEN PLUS continuous glucose monitor system and purchased the RALS IT connectivity system from Medical Automation Systems
Abbott acquired STARLIMS lab IT system and Biofortuna's freeze-dried SSPGo HLA typing kits
Terumo Corporation of Japan merged with CaridianBCT, a blood unit processing company
Perkin Elmer acquired Caliper Life Sciences
Gen-Probe invested $50 million in Pacific Biosciences, known for its SMRT sequencing platform
Quest purchased Celera, a maker of genetic tests
"These announcements are just a small portion of what is really happening," said Rosen. "There are many more deals that have not been announced."
According to the report, a number of totally disparate phenomena have come together for IVD at the same time. Human genome research is finding links between a person's genome and several lifestyle situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions. This has attracted consumer product companies such as Proctor & Gamble and Nestlé to develop products and services based on . Decreases in life science grants have encouraged companies active in this space to migrate their technologies for clinical applications. The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and Life Technologies to the diagnostics market with products and test services. Miniaturization of traditional immunoassay and technologies has finally matured to the point where it may be ready for scale-up and then commercialization into products. This has attracted electronics companies such as Sony, Samsung, Dell Computers and Intel to invest in ventures. Kalorama Information believes these trends are combining to push growth in the 50+ billion-dollar IVD industry.
"" is Kalorama Information's complete report on every segment of in vitro diagnostics including clinical chemistry, molecular, point of care, hematology, histology, blood banking, infectious disease and other areas. The report is over 1400 pages and profiles hundreds of companies in the market.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.08.2012 - 10:25 Uhr
Sprache: Deutsch
News-ID 1144172
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Frenetic Pace of Activity in IVD Over Past Two Years: Kalorama Reports
"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
